Jardiance Gets Heart Failure Nod, But How Long Will Its Reign Last?

 
• By Alaric DeArment

The SGLT2 inhibitor has better efficacy and clearer labeling than Novartis’s Entresto in heart failure with preserved ejection fraction, but AstraZeneca’s Farxiga is expected to produce Phase III data by June.

3D rendering of the Heart valve
Eli Lilly and Boehringer Ingelheim's Jardiance received FDA approval for heart failure with preserved ejection fraction • Source: Shutterstock

More from New Products

More from Scrip